TCR Generation - Medigene AG

Improvement of technologies to generate high-affinity natural TCRs with enhanced sensitivity and safety. Allo-priming technology delivers stronger and more sustained immune responses of TCRs without the need for affinity maturation. Standardization tools like Jovi Tag enable the enrichment of recombinant TCR (rTCR) -expressing T cells to facilitate the selection of safer TCRs.

TCR Generation Publications

Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy

Kathrin Davari, Tristan Holland, Laura Prassmayer, Giulia Longinotti, Kenneth P Ganley, Lisa J Pechilis, Iulia Diaconu, Prashant R Nambiar, Michael S Magee, Dolores J Schendel, Daniel Sommermeyer, Christian Ellinger. Journal for ImmunoTherapy of Cancer; 9(3); 25 March 2021; doi: 10.1136/jitc-2020-002035

Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice

Obenaus, M., Leitão, C., Leisegang, M., Chen, X., Gavvovidis, I., van der Bruggen, P., Uckert, W., Schendel, D.J. and Blankenstein, T. 2015. Nature Biotechnology 33, 402–407 (2015).

Mis-initiation of MART-1 transcription in the thymus and biased TCR usage can explain the high frequency of peripheral MART-1 specific T cells

Pinto, S., Sommermeyer, D., Michel, C., Wilde, S., Schendel, D, Uckert, W., Blankenstein T., Kyewski, B. 2014. Eur J Immunol. 2014 May 20 [Epub ahead of print].

Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity

Schendel, D.J. and Frankenberger, B. 2013. Oncoimmunology. 2013 Jan 1; 2(1):e22410.

Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure

Wilde, S., Geiger, C., Milosevic, S., Mosetter, B., Eichenlaub, S. and D.J. Schendel. 2012. Oncoimmunology. 1(2): 129-140.

Human antitumor CD8+ T cells producing Th1-polycytokines show superior antigen sensitivity and tumor recognition

Wilde, S., Sommermeyer, D., Leisegang, M., Frankenberger, B., Mosetter, B., Uckert, W. and D. J. Schendel. 2012. J Immunol. 189(2): 598-605.

High-quality and high-avidity T cell clones specific for tumor-targeted antigens and how to find them

Wilde, S. and D.J., Schendel. 2012. Oncoimmunology. 1(9):1643-1644.

Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior anti-tumor activity and higher TCR functional avidity

Wilde, S., Sommermeyer, D., Frankenberger, B., Schiemann, M., Milosevic, S., Spranger, S., Pohla, H., Uckert, W., Busch, D.H. and D.J. Schendel. 2009. Blood 114(10): 2131-2139.

TCR Generation Abstracts

CAR-TCR Summit

Combined Molecular & Cellular Tools are Required to Assess Safety of TCR-T Immunotherapies; Tristan Holland

Presentation

SITC Annual Meeting 2020

Development of a CD8 co-receptor independent T cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T cell-based immunotherapy; Davari K, Holland T, Prassmayer L, Longinotti G, Ganley K, Pechilis LJ, Diaconu I, Nambiar PR, Magee MS, Schendel DJ, Sommermeyer D and Ellinger C

Poster

CIMT – Annual Meeting of the Association for Cancer Immunotherapy 2019, Mainz, Germany

A safe and highly active NY-ESO-1/LAGE-1-specific TCR for adoptive T cell therapy of cancer; Longinotti G, Bürdek M, Weis M, Raffegerst S, Mösch A, Schendel DJ, Wehner C

Poster

AACR- American Association for Cancer Research Annual Meeting 2019, Atlanta

In vitro evaluation of TCR efficacy and toxicity using 3D spheroid models; Maja Buerdek, Kathrin Mutze, Kai Pinkernell, Dolores J. Schendel. Medigene Immunotherapies GmbH, Martinsried, Germany

Abstract

Poster

AACR – American Association for Cancer Research Annual Meeting 2017, Washington, D.C., USA

WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC vaccines in AML patients mount specific immune responses and impact progression free survival; Iris Bigalke, Guri Solum, Dag Josefsen, Yngvar Fløisand, Kirsti Hønnåshagen, Lisbeth Skoge, Signe Spetalen, Stein Sæbøe-Larssen, Dolores J. Schendel, Gunnar Kvalheim.

Abstract

Isolation and characterization of a PRAME-specific TCR with high avidity, potent antitumor efficacy and a favorable preclinical safety profile; Manon Weis, Carina Wehner, Christian Ellinger, Susanne Wilde, Dolores J. Schendel. Medigene Immunotherapies GmbH, Planegg/Martinsried, Germany

Abstract

SITC – Society for Immunotherapy of Cancer Annual Meeting 2014, National Harbor MD, USA

Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Weis M., Longinotti G., Sailer N., Schendel D.J., Milošević S. 2014. Generation of tumor antigen specific CD4+ and CD8+ T cells by simultaneous MHC-I and –II epitope presentation in vitro and in vivo. SITC National Harbor, USA.

Download PDF

CIMT – Cancer Immunotherapy Annual Meeting 2013, Mainz

Ellinger C., Wehner C., Wilde S., Schendel D.J., Milošević S. Mai 2013. MHC Class-II Expression Targeting (CrossTAg) for the Generation of Tumor-Antigen-Specific CD4+ T Lymphocytes. CIMT Mainz, Germany.

Download PDF

CIMT – Cancer Immunotherapy Annual Meeting 2013, Mainz

Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Schendel D.J., Milošević S., 2013. Isolation of antigen-specific CD8+ T lymphocytes and molecular characterization of antigenic epitopes. CIMT Mainz, Germany.

Download PDF

Cellular Therapie International Symposium 2013, Erlangen

Wilde S., Mosetter B., Wehner C., Ellinger C., Milosevic S., Frankenberger B., Schendel D. 2013. Isolation of NY-ESO-1-specific T cell receptors restricted by non-HLA-A*02:01 allotypes for TCR gene therapy. Cellular Therapie International Symposium Erlangen, Germany.

Download PDF